Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Twelve of 23 patients with Parkinson's disease and motor fluctuations who entered a double-blind study comparing controlled-release carbidopa/levodopa (Sinemet CR-4) with standard Sinemet (SS) continued into open label follow-up on a combination of CR-4 and SS (C/S); the rest continued on CR-4 alone. Significant improvement on C/S compared with CR-4 was noted for shorter duration and reduced disability of dyskinesias, and more hours 'on' without dyskinesias (all p < 0.05). Total number of hours 'off' was improved on C/S over SS (p < 0.01). Sinemet CR-4 proved to be better than C/S for sleep disturbance (p < 0.05). Although the total number of tablets and doses per day of CR-4 was reduced during the C/S period, total levodopa dosage per day was not significantly changed from either of the previous periods. The C/S therapy for advanced parkinsonism can be more efficacious for fluctuators than either CR-4 or SS alone.

Original languageEnglish (US)
Pages (from-to)101-106
Number of pages6
JournalAnnals of Clinical and Laboratory Science
Volume19
Issue number2
StatePublished - Jan 1 1989

Fingerprint

Parkinson Disease
Dyskinesias
Parkinsonian Disorders
Levodopa
levodopa drug combination carbidopa
Double-Blind Method
Tablets
Labels
Sleep

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Clinical Biochemistry

Cite this

@article{73719128b2a543b68d9836bae4a3ec09,
title = "Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease",
abstract = "Twelve of 23 patients with Parkinson's disease and motor fluctuations who entered a double-blind study comparing controlled-release carbidopa/levodopa (Sinemet CR-4) with standard Sinemet (SS) continued into open label follow-up on a combination of CR-4 and SS (C/S); the rest continued on CR-4 alone. Significant improvement on C/S compared with CR-4 was noted for shorter duration and reduced disability of dyskinesias, and more hours 'on' without dyskinesias (all p < 0.05). Total number of hours 'off' was improved on C/S over SS (p < 0.01). Sinemet CR-4 proved to be better than C/S for sleep disturbance (p < 0.05). Although the total number of tablets and doses per day of CR-4 was reduced during the C/S period, total levodopa dosage per day was not significantly changed from either of the previous periods. The C/S therapy for advanced parkinsonism can be more efficacious for fluctuators than either CR-4 or SS alone.",
author = "Margery Mark and Jacob Sage",
year = "1989",
month = "1",
day = "1",
language = "English (US)",
volume = "19",
pages = "101--106",
journal = "Annals of Clinical and Laboratory Science",
issn = "0091-7370",
publisher = "Association of Clinical Scientists",
number = "2",

}

TY - JOUR

T1 - Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease

AU - Mark, Margery

AU - Sage, Jacob

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Twelve of 23 patients with Parkinson's disease and motor fluctuations who entered a double-blind study comparing controlled-release carbidopa/levodopa (Sinemet CR-4) with standard Sinemet (SS) continued into open label follow-up on a combination of CR-4 and SS (C/S); the rest continued on CR-4 alone. Significant improvement on C/S compared with CR-4 was noted for shorter duration and reduced disability of dyskinesias, and more hours 'on' without dyskinesias (all p < 0.05). Total number of hours 'off' was improved on C/S over SS (p < 0.01). Sinemet CR-4 proved to be better than C/S for sleep disturbance (p < 0.05). Although the total number of tablets and doses per day of CR-4 was reduced during the C/S period, total levodopa dosage per day was not significantly changed from either of the previous periods. The C/S therapy for advanced parkinsonism can be more efficacious for fluctuators than either CR-4 or SS alone.

AB - Twelve of 23 patients with Parkinson's disease and motor fluctuations who entered a double-blind study comparing controlled-release carbidopa/levodopa (Sinemet CR-4) with standard Sinemet (SS) continued into open label follow-up on a combination of CR-4 and SS (C/S); the rest continued on CR-4 alone. Significant improvement on C/S compared with CR-4 was noted for shorter duration and reduced disability of dyskinesias, and more hours 'on' without dyskinesias (all p < 0.05). Total number of hours 'off' was improved on C/S over SS (p < 0.01). Sinemet CR-4 proved to be better than C/S for sleep disturbance (p < 0.05). Although the total number of tablets and doses per day of CR-4 was reduced during the C/S period, total levodopa dosage per day was not significantly changed from either of the previous periods. The C/S therapy for advanced parkinsonism can be more efficacious for fluctuators than either CR-4 or SS alone.

UR - http://www.scopus.com/inward/record.url?scp=0024536814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024536814&partnerID=8YFLogxK

M3 - Article

C2 - 2665626

AN - SCOPUS:0024536814

VL - 19

SP - 101

EP - 106

JO - Annals of Clinical and Laboratory Science

JF - Annals of Clinical and Laboratory Science

SN - 0091-7370

IS - 2

ER -